INTRODUCTION
Two members of the IL-1 cytokine family, IL-1 and IL-18, can promote Th1 and Th17 cell differentiation/activation and the production of IFN-␥ and IL-17 [1] [2] [3] . It is notable that IL-1 or IL-18 also can enhance production of Th2 cytokines, such as IL-9 or IL-13, by mouse mast cells in the presence of an additional signal, such as those induced by IgE/antigen-FcεRI, stem cell factor (SCF), or IL-3 [4 -6] . IL-33 (also called IL-1F11 [7] , NF-HEV [8] , or DVS27 [9] ) is a recently identified member of the IL-1 family of molecules, whose biological activities are mediated in part by its interactions with the receptor ST2 (also called T1, DER-4, Fit-1, or IL-1R4) [7] . Like IL-1␣ [10] , some of the biological activities of IL-33 may also reflect the ability of a precursor/intracellular form of the cytokine to function as an intracrine chromatin-associated nuclear factor, which can regulate transcription [11] .
ST2 is preferentially expressed on Th2 cells in humans [12] and mice [13] and on mouse mast cells [14] , suggesting possible roles for ST2-IL-33 interactions in Th2 cell-associated immune responses. Additional evidence for such roles includes increased serum concentrations of soluble ST2 in patients with exacerbations of asthma [15] , increased expression of ST2 in an asthma model in mice [16] , attenuated development of Th2 cell-and eosinophil-associated airway inflammation in mice after blockade of interactions between ST2 and its ligand [13, 17] , and increased phosphorylation of MAPKs such as JNK, p42/p44, and p38, as well as increased Th2-cytokine production in CD4 ϩ T cells after cross-linking of ST2 [18, 19] . Moreover, ST2-deficient mice exhibit impaired pulmonary granuloma formation, eosinophilia, and Th2 cytokine production after injection of Schistosoma mansoni eggs [20] and decreased IL-5 production by lymph node cells during Nippostrongylus brasiliensis infection [21] . Finally, in addition to enhancing IL-5 and IL-13 production by mouse Th2 cells in vitro [7] , recombinant IL-33 (rIL-33), when administrated to mice in vivo, can induce the development of splenomegaly and eosinophilia in the lungs and gut, as well as elevated numbers of blood eosinophils and increased amounts of serum IgA, IgE, IL-5, and IL-13 [7] .
The binding of IL-33 to ST2 activates a signaling pathway, which involves the recruitment of MyD88, IL-1R-associated kinase 1 (IRAK1), IRAK4, and TNFR-associated factor 6 (TRAF6), leading to the activation of MAPK and NF-B [7] . IL-33 also can enhance MAPK phosphorylation in mouse mast cells [7] , and ST2-deficient mast cells have been reported to exhibit normal histamine release after IgE/antigen stimulation [22] . Apart from that, little is known about the effects of IL-33 on mouse mast cells.
We wished to address two questions concerning the possible effects of IL-33 on mouse mast cells. First, can incubation of mast cells with IL-33 induce effects that are independent of the cells' interactions with IgE? Second, can IL-33 influence the responses of mast cells to IgE? It is well-known that crosslinking of IgE, bound to high-affinity IgE receptors (FcεRI) on mast cells, e.g., with multivalent antigens, initiates mast cell activation, leading to FcεRI aggregation and the subsequent release of various proinflammatory mediators and cytokines [23] [24] [25] [26] [27] [28] [29] . Mast cell activation mediated by IgE/antigen-FcεRI signals can contribute to host defense, e.g., during infections with certain nematodes, whereas pathological mast cell activation can contribute to the development of various allergic and/or autoimmune diseases [23] [24] [25] [26] [27] [28] [29] [30] [31] [32] . Recently, it has been reported that certain IgE antibodies, even in the absence of specific antigens, can enhance the survival, migration, and mediator production of mouse mast cells [33] [34] [35] [36] or chemokine production by human mast cells [37] . Moreover, in the mouse, certain IgE antibodies are more potent in inducing these "cytokinergic" effects than are others [35, 38] . We therefore investigated the effects of IL-1, IL-18, and IL-33 on mouse mast cells incubated in the presence of IgE, with or without specific antigen.
MATERIALS AND METHODS

Preparation of bone marrow-derived, cultured mast cells (BMCMCs)
BMCMCs from C57BL/6J, MyD88-deficient [39] , or Toll/IL-1R domain-containing adaptor-inducing IFN-␤ (TRIF)-deficient [40] mice were obtained by culturing mouse femoral BM cells in WEHI-3-conditioned medium (containing IL-3) for 6 -12 weeks, at which time the cells were Ͼ98% c-kit high FcεRI␣ high by flow cytometry analysis using FITC anti-mouse FcεRI␣ (MAR-1, eBioscience, San Diego, CA, USA) and allophycocyanin (APC) anti-mouse c-kit/ CD117 (2B8, BD PharMingen, San Diego, CA, USA). Wild-type, MyD88 Ϫ/Ϫ , and TRIF Ϫ/Ϫ BMCMCs were similar in appearance by light microscopy and exhibited similar amounts of surface expression of c-kit/CD117, FcεRI, and ST2 by FACS (data not shown). All experiments were performed in compliance with the "Guide for the Care and Use of Laboratory Animals" prepared by the Institute of Laboratory Animal Resources, National Research Council, and published by the National Academy Press (revised 1996) and with the permission of Stanford University Committee on Animal Welfare (Stanford, CA, USA).
FACS analysis
For analysis of cell surface molecules, BMCMCs were incubated with various concentrations of anti-DNP IgE, H1-ε-26 [41] (as a dilution of ascites from mice bearing the H1-ε-26 hypbridoma cell line), or SPE-7 (Sigma Chemical Co., St. Louis, MO, USA; as specified in Results and in the figure legends) in RPMI-1640 media ϩ 10% FCS for 0 -72 h. Cells were incubated with anti-CD16/CD32 mAb (93, eBioscience) for 15 min on ice, then incubated with APC anti-mouse c-kit/CD117 (2B8, eBioscience), and FITC or PE anti-mouse FcεRI␣ (MAR-1, eBioscience), plus PE anti-mouse IL-1R1 (35F5, BD PharMingen), biotin anti-mouse IL-18R␣ (BAF856, R&D Systems, Minneapolis, MN, USA), or FITC or Alexa 647 anti-mouse T1/ST2 (DJ8, MD Biosciences, St. Paul, MN, USA) for 45 min on ice. For detection of IL-18R␣ using biotin-conjugated antibody staining, PE-streptavidin (BD PharMingen) was used as described [3, 42] . The expression of cell surface markers on 7-aminoactinomycin-negative c-kit/CD117 
Cell survival and apoptosis
BMCMCs (1ϫ10 6 /ml) were cultured with 10 ng/ml recombinant mouse (rm)IL-3 (R&D Systems) or with 10 g/ml H1-ε-26 anti-DNP mAb or 5 g/ml SPE-7 anti-DNP mAb in the presence or absence of 100 ng/ml rmIL-1␤ (PeproTech), 100 ng/ml rmIL-18 (R&D Systems), or 100 or 200 ng/ml rhIL-33 (Alexis, San Diego, CA, USA; or PeproTech) for 0 -6 days (for assays of cell survival and apoptosis) or 0, 1, 10, or 100 ng/ml recombinant cytokines for 1 h (for ␤-hexosaminidase release assay). We assessed cell viability by trypan blue staining or by the Annexin V-FITC Apoptosis Detection Kit I (BD PharMingen).
␤-Hexosaminidase release
BMCMC suspensions (8ϫ10 6 cells/ml) were prepared in Tyrodes buffer [containing 10 mM HEPES, pH 7.4, 130 mM NaCl, 5 mM KCl, 1.4 mM CaCl 2 , 1 mM MgCl 2 , 0.1% glucose, and 0.1% BSA (fraction V, Sigma Chemical Co.)]. Concentration (4ϫ; 12.5 l) of anti-DNP IgE mAb (H1-ε-26 or SPE-7, final 10 g/ml) and 12.5 l 4ϫ concentration of cytokine [final 0, 1, 10, or 100 ng/ml rmIL-1␤ (PeproTech), rmIL-18 (R&D Systems), or rhIL-33 (Alexis)] were added into wells of 96-well V-bottom plates (Costar, Corning, NY, USA), and then 25 l 8 ϫ 10 6 cells/ml IgE-sensitized BMCMCs (10 g/ml H1-ε-26 anti-DNP mAb or 5 g/ml SPE-7 anti-DNP mAb, overnight) were added and incubated at 37°C for 1 h. As a positive control, IgE-sensitized BMCMCs (37°C, overnight) were stimulated with 10 ng/ml 2,4-DNP-conjugated human serum albumin (DNP-HSA; Sigma Chemical Co.) or 0.1 g/ml PMA (Sigma Chemical Co.) ϩ 1 g/ml A23187 calcium ionophore (Sigma Chemical Co.). After centrifugation, supernatants were collected. Nonantigen-stimulated, IgEsensitized BMCMCs were treated with 50 l 0.5% (v/v) Triton X-100 (Sigma Chemical Co.), and supernatants were collected. ␤-Hexosaminidase release in supernatants was measured by enzyme immunoassay with p-nitrophenyl-Nacetyl-␤-D-glucosamine (Sigma Chemical Co.) as a substrate. In brief, 10 l culture supernatants were added into wells of 96-well flat-bottom plates, then 50 l 1.3 mg/ml p-nitrophenyl-N-acetyl-␤-D-glucosamine solution in 100 mM sodium citrate (pH 4.5) was added to each well, and the plate was incubated at room temperature for 15-30 min. Glycine (140 l 200 mM, pH 7.0) was added to each well to stop the reaction. Enzymic activities (OD405) were measured by a plate reader. Data show the percent release of ␤-hexosaminidase under various conditions of stimulation relative to the total amount of ␤-hexosaminidase in the cells, as measured in the supernatants of Triton X-100-treated cells.
Cytokine ELISA BMCMCs (1ϫ10 6 /ml) were cultured with or without 10 g/ml H1-ε-26 anti-DNP mAb or 1 or 5 g/ml SPE-7 anti-DNP mAb in the presence or absence of 0 -100 ng/ml rmIL-1␤, rmIL-18, or rhIL-33 for 6 h (with 5 g/ml SPE-7) for 24, 48, or 72 h (with 1 g/ml SPE-7) or in the presence or absence of 100 ng/ml recombinant cytokines [rmG-CSF, GM-CSF, IL-1␣, IL-1␤, IL-2, IL-3, IL-4, IL-6, IL-10, IL-12, IL-13, IL-28B/IFN-3, M-CSF, SCF, and TNF; rhIL-6, IL-13, IL-16, IL-28A/IFN-2, and TGF-␤1 ( 
Statistics
The unpaired Student's t-test, two-tailed, or ANOVA, as appropriate, was used for statistical evaluation of the results.
RESULTS
IL-1R1, T1/ST2, and IL-18R␣ expression on BMCMCs
As reported elsewhere [14] , we found that naïve BMCMCs (no IgE) constitutively expressed T1/ST2 ( Fig. 1) as well as mRNA for IL-1R1 (data not shown); it has been reported that such cells also express mRNA IL-18R␣ [4] . Although we detected IL-1R1 and IL-18R␣ proteins by Western blotting in lysates of BMCMCs (data not shown), naïve BMCMCs did not detectably express IL-1R1 or IL-18R␣ on their cell surface ( Fig. 1) . By contrast, we found that peritoneal mast cells of C57BL/6J mice expressed IL-1R1 (data not shown).
Exposure of naïve BMCMCs to the anti-DNP IgE mAb, H1-ε-26 or SPE-7, for 16 h resulted in marked up-regulation of surface expression of IL-18R␣, but not IL-1R1 (Fig. 1) . The less cytokinergic of these mAb, H1-ε-26, had a greater effect on IL-18R␣ surface expression under these conditions than did SPE-7 (Fig. 1) . Moreover, even the lowest concentrations of IgE tested were sufficient to enhance IL-18R␣ expression. The expression of T1/ST2 was also increased by exposure to SPE-7, but not by H1-ε-26 ( Fig. 1) .
By Western blotting, we detected IL-18R␤ as well as IL-18R␣ proteins in whole cell lysates of naïve BMCMCs (data not shown). However, by FACS, we did not observe IL-18R␤ expression on the surface of such cells using any of three antibodies for IL-18R␤ [BAF1520 (R&D Systems), IMG- 5353A (Imgenex, San Diego, CA, USA), or TC30-28E3 (BD PharMingen); data not shown].
We next examined the kinetics of the effects of IgE on surface expression of IL-1R1, T1/ST2, and IL-18R␣, using 5 g/ml SPE-7 or 10 g/ml H1-ε-26, the concentrations, which induced approximate maximal levels of IL-18R␣ expression (Fig. 1B) . Increased surface expression of T1/ST2 was observed 3 h after SPE-7 exposure, but expression declined by 48 h (Fig. 2, A and B) . Long-term (72 h) exposure to SPE-7 resulted in progressively enhanced IL-18R␣ expression (Fig.  2, A and B) . Exposure to H1-ε-26 promoted IL-18R␣ surface expression to a greater extent than did exposure to SPE-7 but down-regulated T1/ST2 expression time-dependently (Fig. 2, A  and B) . IL-1R1 expression was unaffected by H1-ε-26 or SPE-7 exposure at any time-point examined (Fig. 2, A and B) .
Exposure to SPE-7 IgE but not H1-ε-26 IgE down-regulated kit expression on BMCMCs between 3 and 48 h after exposure, and kit levels returned to baseline by 72 h (Fig. 2C) . Consistent with previous reports [34, 35] , exposure to SPE-7, but not to H1-ε-26, IgE induced substantial IL-6 production by BMCMCs (Fig. 2D ).
These observations are consistent with prior reports indicating that different IgE mAb can have quite different effects on some aspects of mast cell function and that SPE-7 is a much more highly cytokinergic IgE mAb than is H1-ε-26 [33] [34] [35] .
Effects of IL-1␤, IL-18, or IL-33 on BMCMC degranulation and survival
When tested individually at 100 ng/ml, without IgE or in the presence of H1-ε-26 or SPE-7 IgE, none of the cytokines examined promoted BMCMC degranulation (␤-hexosaminidase release; Fig. 3A) .
When tested without IgE, the cytokines had no significant effects on BMCMC survival or apoptosis, at 100 ng/ml (Fig. 3 , B and C) or at 1 or 10 ng/ml (data not shown). The binding of SPE-7 IgE to FcεRI can enhance mouse mast cell survival and cytokine production without promoting degranulation [35, 36] . When tested with either type of IgE, neither IL-1␤ nor IL-18 had any significant effects on BMCMC survival or apoptosis (Fig. 3, B and C) . By contrast, at 1 or 10 ng/ml (data not shown; nϭ3) or at 100 ng/ml (Fig. 3, B and C) , IL-33 reduced BMCMC survival, slightly, albeit significantly, and enhanced apoptosis in the presence of SPE-7 IgE but not H1-ε-26 IgE.
These observations indicate that IL-33 (at concentrations from 1 to 100 ng/ml), but neither IL-1␤ nor IL-18, can negatively regulate BMCMC survival in the presence of SPE-7 IgE. By contrast, none of these cytokines promotes mast cell degranulation in the presence or absence of SPE-7 or H1-ε-26 IgE.
IL-33 induces BMCMC IL-13 production without IgE, and this requires MyD88
It is notable that we found that IL-33, unlike IL-1␤ or IL-18, induced production of IL-6 and IL-13 by naïve BMCMCs in the absence of IgE (Fig. 4) . (Figs. 4 and 5) .
As previously reported [35, 36] , incubation with SPE-7 (5 g/ml), but not H1-ε-26 (10 g/ml), IgE for 6 h induced IL-4, IL-6, and IL-13 production by naïve BMCMCs (Fig. 4) . Each cytokine tested (IL-1␤, IL-18, or IL-33) enhanced SPE-7 IgEinduced production of IL-6 and IL-13, but not IL-4, by BMCMCs (Fig. 4) . However, IL-33 enhanced IL-6 and especially, IL-13 cytokine production much more strongly than did IL-1␤ or IL-18. For example, the IL-13 production induced by 100 ng/ml IL-33 in the presence of SPE-7 (ϳ350 ng/ml) was approximately sevenfold that (ϳ50 ng/ml) induced by 100 ng/ml IL-1␤ or IL-18 (Fig. 4) . IL-33 also enhanced the production of IL-6 and IL-13 by mast cells incubated for up to 72 h in the presence or absence of a low concentration of SPE-7 IgE (1 g/ml).
MyD88 is required for signal transduction via IL-1/IL-1R1 or IL-18/IL-18R [39] . We found that IL-33-mediated phosphorylation of p38 and ERK1/2 was reduced markedly in MyD88 Ϫ/Ϫ BMCMCs (Fig. 7) . By contrast, MyD88 appeared to make little or no contribution to SPE-7 IgE-mediated phosphorylation of p38 and ERK1/2 (Fig. 7) . By contrast, TRIF was not required for SPE-7 IgE-or IL-33-mediated phosphorylation of p38 and ERK1/2 (Fig. 7) . As shown in Figure 3 , B and C, we found that 100 ng/ml rhIL-33 slightly reduced SPE-7 IgEdependent enhancement of mast cell survival. We therefore were surprised to find that at 200 ng/ml, IL-33, like SPE-7, enhanced mast cell survival significantly (Fig. 8A) . However, the combination of SPE-7 and IL-33 markedly reduced the survival of wild-type (MyD88 ϩ/ϩ and TRIF ϩ/ϩ ) BMCMCs (Fig.  8A) . SPE-7 IgE significantly enhanced survival in wild-type, MyD88 Ϫ/Ϫ , or TRIF Ϫ/Ϫ BMCMCs, whereas the ability of IL-33 to enhance survival was impaired significantly in MyD88 Ϫ/Ϫ BMCMCs but not in TRIF Ϫ/Ϫ BMCMCs (Fig. 8A ). MyD88 but not TRIF also appeared to be required for the ability of IL-33 (at 200 ng/ml) to reduce BMCMC survival in the presence of 5 g/ml SPE-7 IgE (Fig. 8A) .
IL-33-mediated IL-6 and IL-13 production was also virtually abolished in naïve or SPE-7 IgE (5 g/ml)-sensitized BMCMCs, which were genetically deficient in MyD88 (Fig.  8B) . By contrast, BMCMCs deficient in TRIF, which is required in addition to MyD88 for propagation of TLR signals [40] , exhibited levels of IL-6 and IL-13 production in response to IL-33, statistically indistinguishable from those observed with wild-type BMCMCs (Fig. 8B) .
Taken together, these observations indicate that MyD88, but not TRIF, is required for IL-33-mediated signal transduction and for the ability of IL-33 to influence survival and promote cytokine production in mouse BMCMCs.
DISCUSSION
We found that IL-33, but not IL-1␤ or IL-18, can enhance IL-6 and IL-13 production by naïve BMCMCs in the absence of IgE. That IL-33 has this effect on mouse mast cells is quite remarkable; except for IL-3 and SCF, which are mast cell growth and survival factors, IL-33 was the only cytokine among the many other mouse cytokines tested, which was able to induce IL-6 and IL-13 production by naïve BMCMCs. Moreover, although all three IL-1 family cytokines examined (IL-1␤, IL-18, and IL-33) enhanced IL-6 and IL-13 production by BMCMCs in the presence of the potently cytokinergic IgE mAb, SPE-7, the effect of IL-33 was much stronger than that of IL-1␤ or IL-18. IL-33 also enhanced the IL-6 and IL-13 production induced by specific antigen (DNP-HSA) stimulation of BMCMCs, which had been sensitized with SPE-7 or the more weakly cytokinergic IgE mAb, H1-ε-26 (data not shown). Our findings offer a new perspective about previously published findings concerning the effects of IL-33 in vivo. Schmitz et al. [7] demonstrated that treatment of mice with rIL-33 resulted in inflammation of the lungs and the gastrointestinal tract, which was associated with eosinophil recruitment, and resulted in elevations of serum concentrations of IgA, IgE, IL-5, and IL-13. Moreover, they showed that IL-33-mediated inflammation was abolished in IL-13-deficient mice [7] . As mast cells are present in the lungs and gut, and mast cells represent one potential source of IL-13, our in vitro findings raise the possibility that IL-33 can induce IL-13-dependent inflammation in vivo in part by inducing IL-13 production by mast cells.
In contrast to its strong effects on mouse mast cell cytokine production, IL-33 neither induced mouse mast cell degranulation in vitro, as assessed in our study by ␤-hexosaminidase release, nor is required for the induction of mast cell degranulation by IgE-FcεRI-dependent signaling. For example, mast cells derived from ST2-deficient mice exhibited no abnormalities in histamine release after IgE/antigen stimulation or in IL-4 production after treatment with PMA ϩ ionomycin [22] .
Although IL-33 clearly can have dramatic effects on mouse mast cell cytokine production in vitro, the influence of IL-33/ ST2 interactions on mast cell function in vivo remains to be determined. It was reported that ST2-deficient mice, which had been sensitized with OVA admixed with the adjuvant aluminium hydroxide (alum), exhibited no impairment in the development of OVA-induced allergic airway inflammation [22] . This protocol for OVA sensitization and challenge, which results in the development of airway hyperreactivity (AHR) and Th2-dominant and eosinophil-rich pulmonary inflammation, is now widely used as a model for asthma [43] . However, mast cells [44, 45] , B cells [46] , IgE/FcεRI interactions [47] , IL-1 [48, 49] , and TNF [50] are not essential for the development of OVA-induced AHR and/or pulmonary inflammation induced in mice sensitized by injection of OVA admixed with alum. By contrast, such cells and mediators are crucial for the development of OVA-induced AHR and/or pulmonary inflammation induced in mice sensitized by injection of OVA without alum [45, [47] [48] [49] [50] . Therefore, we think that it is more likely that IL-33/ST2-dependent effects (on mast cells or other cell types) may influence models of Th2-associated inflammation, which are induced in mice having been sensitized without alum than in those sensitized with standard protocols using that adjuvant. Fig. 3 . Effects of IL-1␤, IL-18, or IL-33 on mouse mast cell degranulation, survival, and apoptosis. (A) Naïve BMCMCs were cultured in the presence or absence of 10 g/ml H1-ε-26 IgE or 5 g/ml SPE-7 IgE, with or without 100 ng/ml IL-1␤, IL-18, or IL-33 for 1 h. As positive controls, naïve BMCMCs were stimulated with PMA ϩ ionomycin (PϩI), or BMCMCs sensitized with anti-DNP IgE (H1-ε-26 or SPE-7) overnight were cultured with DNP-HSA for 1 h. Extent of mast cell degranulation was assessed as percent ␤-hexosaminidase release. Data are the average Ϯ SD of triplicate determinations in one of three experiments we performed, each using different batches of BMCMCs and each of which gave similar results. *, P Ͻ 0.05, versus the corresponding values for BMCMCs incubated without IgE (by Student's t-test, two-tailed). (B and C) Naïve BMCMCs were cultured for the indicated number of days with medium alone, 10 ng/ml rmIL-3, 10 g/ml H1-ε-26 IgE, or 5 g/ml SPE-7 IgE; or 100 ng/ml IL-1␤, IL-18, or IL-33 in the presence or absence of 10 g/ml H1-ε-26 IgE or 5 g/ml SPE-7 IgE. In CD4 ϩ T cells, cross-linking of ST2 induced the phosphorylation of MAPKs such as JNK, p42/p44, and p38 [18, 19] . Moreover, IL-33-dependent signaling through ST2 involves the recruitment of MyD88, IRAK1, IRAK4, and TRAF6 and results in the activation of MAPK and NF-B [7] . Schmitz et al. [7] reported that IL-33 can enhance MAPK phosphorylation in mouse mast cells. We confirmed that IL-33 can activate MAPK (ERK1/2 and p38) phosphorylation in mouse mast cells and showed that this process, as well as IL-33-induced production of IL-6 and IL-13, depends, importantly, on a pathway involving MyD88 but not TRIF.
The biological consequences of IL-33/ST2 interactions appear to be quite complex, depending on the type of ST2-expressing cell, the concentration of IL-33, and other factors. For example, macrophages treated with soluble ST2 or deficient in ST2 exhibited increased proinflammatory cytokine production by LPS [51] [52] [53] , suggesting that ST2 functions as an inhibitory receptor in such settings. By contrast, we have established that IL-33 has activating or with IgE, coactivating functions in mouse mast cell cytokine production. Moreover, we have observed that IL-6 and TNF production by LPSstimulated BMCMCs was enhanced significantly by the addition of rhIL-33 (unpublished observation). Thus, in mouse mast cells (our data) and in human mast cells [54] , IL-33 can initiate or enhance cell activation pathways leading to cytokine secretion.
However, depending on its concentration, IL-33 appears to be able to exert positive or negative effects on mouse mast cell survival. We found that at concentrations of 1, 10, or 100 ng/ml, IL-33 significantly, albeit slightly, reduced the enhancement of BMCMC survival induced when the cells were incubated with the potently cytokinergic IgE mAb, SPE-7. By contrast, at 200 ng/ml, IL-33 significantly increased survival of BMCMCs in the absence of IgE but markedly decreased their survival when the cells were coincubated with SPE-7 IgE. We do not yet understand why, depending on the circumstances, IL-33 can exhibit such distinct effects on BMCMC survival in vitro nor do we know whether any of these effects can be detected in vivo. In addition to analyzing effects of IL-33 on mast cells, we investigated the effects of IL-1␤ and IL-18. It has been reported that IL-1␤ or IL-18 can enhance IL-9 or IL-13 production by BMCMCs, which have been stimulated with IgE and specific antigen or IgE and anti-IgE [4 -6] . We showed that in the absence of specific antigens recognized by IgE, IL-1␤ or IL-18 enhanced IL-6 and IL-13 production by BMCMCs, which had been sensitized with the SPE-7 IgE mAb but not with the less potently cytokinergic IgE mAb, H1-ε-26. These effects of IL-1␤ or IL-18 on BMCMC cytokine production occurred without detectably inducing mast cell degranulation.
The effect of IL-1␤ on BMCMC cytokine production is particularly notable, given that IL-1R1 expression was hardly detectable on naive BMCMCs or on cells sensitized with SPE-7 or H1-ε-26 IgE. Despite our inability to detect IL-1R1 surface expression on mouse BMCMCs under the conditions tested, we (this study) and others [5, 6] have detected effects of IL-1 on mouse mast cell function. These results are reminiscent of findings in T cells, in that IL-1 can promote Th1 or Th17 cell differentiation and IFN-␥ or IL-17 production by Th1 or Th17 cells, respectively [1, 3] , although expression of IL-1Rs is hardly detectable by FACS analysis on the surface of such T cells [3, 55] . Similarly, TNF, another potent proinflammatory cytokine, can also promote Th1/Th17 cell differentiation and IFN-␥ or IL-17 production by Th1 or Th17 cells, respectively [3] , although such cells exhibit little or no detectable surface expression of TNFR by FACS analysis [3] .
Sensitization with H1-ε-26 IgE enhanced IL-18R␣ surface expression more strongly on BMCMCs than did sensitization with SPE-7 IgE, but IL-18 did not detectably promote cytokine production in H1-ε-26-sensitized BMCMCs. However, when we maintained H1-ε-26-or SPE-7-sensitized BMCMCs in the presence of specific antigen (DNP-HSA) for 6 h, surface expression of IL-18R␣, but not IL-1R1, was up-regulated to levels higher than those observed in BMCMCs, which had been incubated with the same mAb but in the absence of antigen (data not shown). Moreover, IL-1␤ or IL-18 enhanced IL-6 and IL-13 production by BMCMCs sensitized with H1-ε-26 or SPE-7 when the cells were maintained for 6 h in the presence of the specific antigen DNP-HSA (data not shown).
Taken together, our observations provide additional evidence that IL-1␤ or IL-18 can enhance mast cell cytokine production in the presence of IgE-FcεRI-derived signals.
In summary, we found that IL-33 can induce naïve mouse mast cells to secrete IL-6 or IL-13 in vitro and can enhance production of these cytokines in mast cells, which are also stimulated via IgE or IgE and specific antigens. We also found that at 200 ng/ml, IL-33 enhanced mouse mast cell survival significantly in the absence of IgE or exogenous growth factors. Thus, the effects of IL-33 in mouse mast cells are similar to those reported recently for IL-33 in human umbilical cord blood-derived mast cells (HUCBMCs). Specifically, we found recently that IL-1␤, IL-18, or IL-33 induced phosphorylation of Erk, p38, and JNK in naive HUCBMCs and that IL-33 or IL-1␤ also induced IL-8 and IL-13 production in naïve HUCBMCs and enhanced production of these cytokines in HUCBMCs stimulated with IgE and anti-IgE, without enhancing secretion of PGD 2 or histamine [54] . IL-33 or IL-1␤, but not IL-18, also enhanced the survival of naive HUCBMCs [54] . Based on the effects of IL-33 in mouse or human mast cells in vitro, it is tempting to speculate that IL-33 may contribute to the development or perpetuation of mast cell-dependent, immune responses or disease processes in vivo.
